Navigation Links
Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

JACKSONVILLE, Fla. and ALEXANDRIA, Va., May 8 /PRNewswire-USNewswire/ -- New recommendations released today by a consensus group of the American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) are calling for major changes in the way health care professionals treat hospitalized patients with high blood glucose (sugar) levels. The authors recommend revised glucose targets of 140-180 mg/dL in the ICU setting, and between 100-180 mg/dL for most patients admitted to general medical-surgical wards.


The recommendations, which were published online today and will appear in the June issues of Endocrine Practice (Link here) and Diabetes Care (Link here), come at a time when attempts to intensively manage glucose targets in the ICU setting have shown inconsistent results in patient outcomes. Several recent randomized controlled clinical trials in critically ill patients in ICUs with diabetes or elevated blood glucose levels have failed to show a significant improvement in mortality with intensive insulin therapy to achieve near normal glucose levels. Moreover, a large newly-published randomized controlled trial showed an increase in mortality risk associated with intensive control of glycemia targeting blood glucose of 80-110 mg/dL. These outcomes have raised concerns regarding specific glycemic targets and the means for achieving them in both critically and non-critically ill patients.

Recognizing the importance of glycemic control across the continuum of care, experts from AACE and ADA were invited to develop an updated consensus statement on inpatient glycemic management.

After a thorough analysis of all the published trials, the authors believe that patients with elevations in blood glucose should continue to be carefully treated, but to less intensive blood glucose targets than were previously suggested. The authors recommend revised glucose targets of 140-180 mg/dL for critically ill patients in ICU settings.

"We are witnessing an evolution in the management of hyperglycemia in inpatient settings," Dr. Etie S. Moghissi, AACE Chair of the Inpatient Glycemic Control Consensus Panel said. "Despite some inconsistencies in the clinical trial results, it would be a serious error to conclude that judicious control of glycemia in hospitalized patients is not warranted."

The complexity of inpatient glycemic management necessitates a system approach that facilitates safe practices that reduce the risk for errors and episodes of severe hypoglycemia. The consensus group recommends a multidisciplinary approach for care from admission to discharge from the hospital.

"The responsibility for management of hyperglycemia shifts from the health care team to the patient following hospital discharge," said Dr. Mary Korytkowski, ADA Chair of the Inpatient Glycemic Control Consensus Panel. "It is therefore important that patients receive the information necessary to safely manage this aspect of their care once they are at home."

Members from the AACE/ADA Inpatient Glycemic Control Task Force will discuss the new AACE/ADA consensus statement highlighting the relationship between glycemic control and clinical outcomes during special symposium scheduled on Friday 7:15 p.m., May 15, 2009 at the AACE 18th Annual Meeting & Clinical Congress in Houston, Texas.

About the American Association of Clinical Endocrinologists (AACE)

AACE is a professional medical organization with more than 6,200 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. For more information, please call the AACE office at 904-353-7878 or visit

About the American Diabetes Association (ADA)

The American Diabetes Association is leading the fight against the deadly consequences of diabetes and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit Information from both these sources is available in English and Spanish.

SOURCE American Association of Clinical Endocrinologists; American Diabetes Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
3. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
4. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
5. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
8. Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
9. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
10. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
11. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
Post Your Comments:
(Date:10/13/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ... focused on the development and commercialization of targeted ... previously announced underwritten public offering of 5,000,000 shares ... up to 3,000,000 shares of the Company,s common ... public of $3.00. The shares of common stock ...
(Date:10/13/2015)... , Oct. 13, 2015  Human Longevity, Inc. (HLI), ... of medicine, announced today the launch of the company,s ... that has the potential to transform healthcare. The inaugural ... CA , at HLI,s headquarters facility. More Health ... other US and International cities. ...
(Date:10/13/2015)... 13, 2015  Measurement in accountable care programs ... financial incentives, but gaps in measurement can result ... health systems. A new, peer-reviewed study published ... explores measurement gaps for high-priority conditions ... --> --> "These ...
Breaking Medicine Technology:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... first high-tech foam roller with 11 hours of vibrating power. Tested by Olympic ... recovery time and increase athletic performance. , Mark's background in sporting equipment and ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Vision Group Holdings, ... of San Diego, California. With brands including The LASIK Vision Institute and TLC Laser ... it the nationwide leader in laser vision correction. , Global Laser Vision will continue ...
(Date:10/13/2015)... PA (PRWEB) , ... October 13, 2015 , ... "My ... digging his fists into his infected cheeks," said an inventor from Platteville, Colo. "I ... their skin problems." , He developed the UNTOUCHABLE to prevent a child from rubbing ...
(Date:10/13/2015)... ... October 13, 2015 , ... HealthAware , headquartered ... Patient Engagement Summit . HealthAware is a technology company focused on the ... interventions via mobile devices that provide a framework for the development of healthy ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... workflow solutions, announced today their sponsorship of the Microsoft Dynamics AXUG, GPUG and ... AXUG Summit, GPUG Summit and NAVUG Summit are independent user conferences designed and ...
Breaking Medicine News(10 mins):